Ch 1. Targeted Therapy for Metastatic Renal Cell Carcinoma : Overview- Ronald M. Bukowski, Robert A. Figlin, and Robert Motzer- Ch 2. Molecular Genetics of Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes - W. Marston Linehan, Nadeem Dhanani, Cathy Vocke, and Gennady Bratslavsky- Ch 3. Molecular Targets in Renal Tumors: Pathologic Assessment - Ming Zhou- 4.Cytokines: Therapeutic Results and Molecular Basis of Activity - Thomas Hutson and Ernest C. Borden- Ch 5. VHL and HIF in Clear Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications - William Kaelin and Daniel J. George - Ch 6. Vascular Endothelial Growth Factor (VEGF): Biologic Aspects and Clinical Approaches - W. Kimryn Rathmell and Brian Rini- Ch 7A. VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition - John S. Lam, Robert Figlin, and Arie Belldegrun- Ch 7B. Sunitinib and Axitinib in Renal Cell Carcinoma- Robert Motzer- Ch 7C. Sorafenib in Renal Cell Carcinoma- Saby George and Ronald M. Bukowski- Ch 7D. Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: - Brian Rini- Ch 8. Integrin a5ß1 as a Novel Therapeutic Target in Renal Cell Carcinoma- Vanitha Ramakrishnan, Vinay Bhaskar, Melvin Fox, Keith Wilson, John Cheville, and Barbara Finck- Ch 9A. Carbonic Anydrase IX: Biological and Clinical Approaches- Arie Belldegrun, Robert A. Figlin, and Brian Shuch- Ch 9B. Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biologic and Clinical Studies - Jeannette C. Oosterwijk-Wakka, Otto C. Boerman, Peter F. A. Mulders, and Egbert Oosterwijk- Ch 10. Chemokines in Renal Cell Carcinoma : Implications for Tumor Angiogenesis and Metastasis- Karen Reckamp, Robert A. Figlin, and Robert M. Strieter- Ch 11. PI3K/Akt/mTOR Pathway: A Growth Proliferation Pathway - Daniel Cho, James Mier, and Michael B. Atkins- Ch 12. EGFR/HER2: Relevance in Renal Cell Carcinoma - Eric Jonasch and Cheryl Walker- Ch 13. Proteosome - NFkB Signaling Pathway : Relevance in Renal Cell Carcinoma - Ram Ganapathi, Susan A.J. Vaziri, and Jorge Garcia- Ch 14. The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma - Donald P. Bottaro, Benedetta Peruzzi, and Jean-Baptise Lattouf- Ch 15. Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Carcinoma - Yoichi Mizutani, Akihiro Kawauchi, Benjamin Bonavida, and Tsuneharu Mmiki- Ch 16. EpH2A: A Novel Target in Renal Cell Carcinoma- Mayumi Kawabe, Christopher Herrem, James Finke, and Walter Storkus- Ch 17. Restoring Host Immunity: How Coregulatory Molecules are Changing the Approach to Management of Renal Cell Carcinoma- Brant A. Inman, Xavier Frigola, Haidong Dong, James C.Yang, and Eugene Kwon- Ch 18. The Role of Gangliosides in Renal Cell Carcinoma- Phillip Shaheen, Ronald M. Bukowski, and James Finke- Ch 19. Tumor Necrosis Factor Misnomer and Therapeutic Target- Marina Parton, Tanya Das, Gaurisankar Sa, James Finke, Tim Eisen, and Charles Tannenbaum- Ch 20. Molecularly Targeted Staging Strategies in Renal Cell Carcinoma- Mark Nogueira and Hyung Kim- 21. Adjuvant therapy for Renal Cell Carcinoma : Targeted Approaches - Karin Kader and Christopher Wood
EAN/ISBN : 9781597453325
Publisher(s): Springer, Berlin, Humana Press
Format: ePub/PDF

Author(s): Bukowski, Ronald M. - Figlin, Robert A. - Motzer, Robert J.